A study in which the VHIO has participated would seem to show that the combination of durvalumab, an anti-PD-L1 monoclonal…
Genitourinary, CNS and Sarcoma Tumors Program
In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…
